Morgan Stanley had a $25.00 price target on this stock only a few weeks ago. The company has $85,000,000 in cash which will fund it through the end of 2007 at the earliest. The partial halt to the trial was based on elevated enzymes in the liver - a condition which is not unusual - in three patients out of 600. The drug is already approved in Europe for fighting cancer. The company has two other drugs in the pipeline. By any reasonable measure the market cap of this company should be in the $350 million range as a minimum. The stock was added to the NASDAQ Bio-Tech index on Monday. Not one brokerage put a sell rating on the stock. The current low share price is total manipulation by the "big boys" - very soon they will have all the cheap shares they want and within 30 days THLD will be above $7.00 and you'll be asking yourself , �Why didn�t I buy it at $4.00?
As the C.E.O. expressed at the B of A Health Care Conference held last Tuesday the company's management fully expects the trials to resume as soon as the F.D.A. reviews the company's response.
TH-070 is at the forefront and an already proven and effective prostate drug beyound any other in the market.
Note the efficacy in the webcast of the drug in just TWENTY-EIGHT DAYS, along with the results from longer trials.
Note the efficacy compared all other drugs in the BPH space, and how TH-070 is a MAGNITUDE better.
"It's unfortunate that the "wash rule" takes 30 days. Many of the shareholders who owned it at $15.00 and sold on the drop to take the tax loss are on the sidelines in pain waiting to be able to buy back in. They will when the 30 day �wash period� expires in a few weeks. Buy it here before you have to compete with the old shareholders.
The market for the drug is over $3 Billion dollars. Morgan Stanley said that the drug could become the "Gold Standard" for treating enlarged prostrates. A partnership or a buyout is quite likely. Good luck to all!! This is a great buy.